Our People » Our Network
PHARMNOVO IS A BIOPHARMA COMPANY performing research and development in collaboration with internationally leading academic and pharmaceutical scientists in their fields related to pain and pain therapy.
THE PRE-CLINICAL PHASE of the PN6047 development project is fundamentally complete and planning is now in train for regulatory toxicology testing and first in man clinical trials. The regulatory toxicology programme is being designed in collaboration with selected experts who will advise and manage the conduct and analysis of the animal testing.
Clinical input into the remaining phases of the project is clearly necessary and PharmNovo has put together a first class clinical team. The team includes; Andrew Rice, Professor of Pain Research, Imperial College, London; (link), Dr Roger Knaggs, Associate Professor in Pharmacy Practice, University of Nottingham (link), Chair of the UK Clinical Pharmacy Association pain management group) and Dr Peder Andersson, Chief Executive Officer, Biosergen.
Together with Board member Dr Anthony Ford, the team has huge experience of overseeing clinical testing of new drugs, interaction with regulatory bodies and progression to the market.
Per von Mentzer, CEO, presented PN6047 at the Neurology Event at RedEye on October 23. Take the opportunity to listen to a very interesting live presentation and learn more about PN6047, the unique first-in-class phase II ready asset with break-through potential in treatment of neuropathic pain. PN6047 demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. These findings suggest a promising path forward in the field of pain management.
Read morePharmNovo attended the LSX Nordic Congress in Copenhagen 8-9 October and Per von Mentzer, CEO presented PN6047, a unique first-in-class phase II ready asset with break-through potential in treatment of neuropathic pain. Being one of 68 companies that have recently been awarded by EIC for up to 17.5 MEUR (2.5 MEUR grant and up to 15 MEUR equity) from a total of 969 applicants is a strong validation of the potential of the phase II ready asset PN6047 and of PharmNovo. Take the opportunity to listen to the presentation here:
Read morePharmNovo is very pleased to announce that we have been awarded a 2.5 MEUR grant and an opportunity for up to 15 MEUR equity investment from the European Innovation Council (EIC) for innovative pain treatment. The equity part being contingent on investments of equal amounts from co-investors.
Read moreOn May 29–30, BioStock hosted the Global Forum. The event is the first of its kind, aimed at bringing together growth stage Nordic life science companies looking to expand into new markets and experts armed with a profound knowledge of how business is done across the globe.
Read more
